Shoulder Innovations (NYSE:SI) Major Shareholder Sells $47,347.00 in Stock

Key Points

• Major shareholder Gilde Healthcare sold 2,095 Shoulder Innovations shares for $47,347 at an average price of $22.60, reducing its position by 0.09% while retaining about 2.21 million shares.
• SI shares fell 8.4% to $20.54 in Friday trading, despite reporting quarterly revenue of $16.71 million and an EPS loss of $0.41 that beat analyst expectations.
• Analyst sentiment remains generally positive: six analysts rate the stock a Buy, with a consensus “Moderate Buy” rating and an average price target of $23.33.

Shoulder Innovations, Inc. (NYSE:SI - Get Free Report) major shareholder Healthcare Holding B.V. Gilde sold 2,095 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $22.60, for a total value of $47,347.00. Following the completion of the sale, the insider owned 2,212,207 shares of the company's stock, valued at approximately $49,995,878.20. This trade represents a 0.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.

Healthcare Holding B.V. Gilde also recently made the following trade(s):

• On Wednesday, August 5th, Healthcare Holding B.V. Gilde sold 7,338 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.64, for a total value of $166,132.32.
• On Tuesday, August 4th, Healthcare Holding B.V. Gilde sold 99,812 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.77, for a total transaction of $2,272,719.24.
• On Monday, August 3rd, Healthcare Holding B.V. Gilde sold 10,751 shares of Shoulder Innovations stock. The shares were sold at an average price of $22.71, for a total transaction of $244,155.21.
• On Friday, July 31st, Healthcare Holding B.V. Gilde sold 20,034 shares of Shoulder Innovations stock. The stock was sold at an average price of $22.73, for a total transaction of $455,372.82.
• On Thursday, July 30th, Healthcare Holding B.V. Gilde sold 28,245 shares of Shoulder Innovations stock. The shares were sold at an average price of $23.36, for a total transaction of $659,803.20.

Shoulder Innovations Stock Down 8.4%

SI traded down $1.89 during trading hours on Friday, reaching $20.54. 286,871 shares of the stock traded hands, compared to its average volume of 93,468. Shoulder Innovations, Inc. has a fifty-two week low of $10.92 and a fifty-two week high of $24.59. The company has a market cap of $426.06 million and a price-to-earnings ratio of -0.12. The company has a debt-to-equity ratio of 0.11, a current ratio of 11.81 and a quick ratio of 10.04. The firm's fifty day simple moving average is $19.79 and its two-hundred day simple moving average is $16.04.

Shoulder Innovations (NYSE:SI - Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.41) EPS for the quarter, topping analysts' consensus estimates of ($0.44) by $0.03. The firm had revenue of $16.71 million for the quarter. Shoulder Innovations had a negative net margin of 81.78% and a negative return on equity of 35.11%. As a group, analysts forecast that Shoulder Innovations, Inc. will post -1.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on SI shares. UBS Group initiated coverage on Shoulder Innovations in a research note on Tuesday, July 28th. They set a "buy" rating and a $27.00 price objective for the company. Piper Sandler reaffirmed an "overweight" rating and issued a $25.00 target price (up from $19.00) on shares of Shoulder Innovations in a research report on Friday. Weiss Ratings upgraded Shoulder Innovations from a "sell (d-)" rating to a "sell (d)" rating in a research note on Monday. Finally, BTIG Research lifted their price target on shares of Shoulder Innovations from $24.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $23.33.

Trending Headlines about Shoulder Innovations

Here are the key news stories impacting Shoulder Innovations this week:

• Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
• Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
• Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
• Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
• Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
• Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale

Hedge Funds Weigh In On Shoulder Innovations

A number of hedge funds have recently bought and sold shares of SI. Bank of America Corp DE raised its stake in Shoulder Innovations by 43.7% during the first quarter. Bank of America Corp DE now owns 26,983 shares of the company's stock valued at $392,000 after buying an additional 8,205 shares in the last quarter. Royal Bank of Canada grew its position in shares of Shoulder Innovations by 7,046.3% in the 1st quarter. Royal Bank of Canada now owns 53,883 shares of the company's stock worth $783,000 after acquiring an additional 53,129 shares in the last quarter. KCM Capital Inc bought a new stake in shares of Shoulder Innovations in the 1st quarter valued at approximately $509,000. Roubaix Capital LLC raised its position in shares of Shoulder Innovations by 61.9% during the 1st quarter. Roubaix Capital LLC now owns 257,121 shares of the company's stock valued at $3,736,000 after acquiring an additional 98,305 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Shoulder Innovations in the first quarter worth $252,000.

Shoulder Innovations Company Profile

Shoulder Innovations NYSE: SI is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source